Macopharma Press Release

Thursday October 15, 2020

The first application of convalescent THERAFLEX MB-Plasma in Germany

For the first time, convalescent plasma treated with the THERAFLEX MB-Plasma procedure was successfully transfused to a patient with COVID-19 in Germany.

The plasma was locally obtained from donors who have recovered from COVID-19, the German Red Cross Blood Service NSTOB applied the THERAFLEX MB-Plasma procedure and two units were transfused to one patient in Oldenburg, Germany¹.

The patient had a variety of symptoms, a weakening general condition and persistent high fever. Very shortly after the treatment, the patient improved steadily, the fever rapidly decreased and the patient could be discharged from the hospital.



Happy about new therapy option with convalescent plasma produced in Oldenburg: Prof Dr Axel Hamprecht (Oldenburg Clinics), Dr Regina Prenzel (Pius Hospital) and Dr Eduard Petershofen (German Red Cross Blood Service).

About THERAFLEX MB-Plasma

The THERAFLEX MB-Plasma System has a Class III CE Mark (available for sale in countries where the CE mark is accepted) and is not currently available for sale in the United States. It is a user-friendly in-house treatment for single units of plasma. The GMP-conforming procedure is adapted for the inactivation of FFP from aphaeresis or whole blood plasma. The MB plasma system uses a combination of a membrane filter Plasmaflex PLAS4, (which removes residual leucocytes, red cells, platelets and aggregates, intra-cellular viruses and minimises the amount of microvesicles and microparticles), a dry Methylene Blue pill, visible light and a Blueflex Methylene Blue removal filter.

¹ Press release published on by **Pius-Hospital Oldenburg on September 18, 2020 (https://www.pius-hospital.de/aktuell/pressemitteilungen/zum-ersten-mal-covid-19-erkrankung-antikoerpern-behandelt)**



We support life

About German Red Cross Blood Transfusion Service NSTOB

Blood supply for the Region – around the clock

The German Red Cross Blood Transfusion Service NSTOB is a non-profit (private) limited company of the Blood Center of the German Red Cross chapters of Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg and Bremen. With more than 800 employees on 8 sites, we supply hospitals as well as resident physicians with medicinal products derived from human blood in our catchment area. We provide 24-hour-transfusion-related laboratory services 365 days a year. The health and wellbeing of our patients as well as the safety of our blood donors are our highest priority.

As a non-profit (private) limited pharmaceutical company, we organize 10,000 blood donation appointments to ensure the blood supply. We run production facilities, medical laboratories and a research and development unit.

Together with our 35 000 honorary helpers and more than 400 000 active blood donors, we build the basis of the blood donor transfusion service in our supply area. We are part of a vibrant and unique community under the auspices of the German Red Cross and we thus offer a unique supply system in Germany.

About Pius Hospital, Oldenburg

Kindness. Expertise. Safety.

With overall 1,350 employees, the Pius-Hospital Oldenburg takes care of patients from the whole Weser-Ems-Region in north-western Germany. With 420 beds, our hospital is the largest Catholic hospital in this area. We apply state-of-the-art medical technology for diagnostics and therapy to ensure the best possible treatment reflecting the current state of research in the field. Offering a spectrum of medical services which is as broad as it is profound our specialities are in the fields of oncology, gynaecology, pneumology, thoracic and vascular surgery, visceral surgery and endoprosthetics. We treat inpatients as well as outpatients that annually make up for 76,000 treatment cases.

¹ Press release published on by **Pius-Hospital Oldenburg on September 18, 2020** (<u>https://www.pius-hospital.de/aktuell/pressemitteilungen/zum-ersten-mal-covid-19-erkrankung-antikoerpern-behandelt</u>)



We support life

About Macopharma

Macopharma creates quality innovative blood products and bio-sourced therapies for patients. We are dedicated to raising the standards of care by relying on close relationships with our suppliers and users and questioning ourselves constantly to become the world's most trusted healthcare partner.

Maintaining confidence by committing to a comprehensive business continuity plan and a sustainable development while fighting against all forms of discrimination are part of our values. We also believe that working collaboratively is a key element to meet challenges and imagine tomorrow's products and services.

As yesterday and today, we will continue to support life in the future.

¹ Press release published on by **Pius-Hospital Oldenburg on September 18, 2020** (https://www.pius-hospital.de/aktuell/pressemitteilungen/zum-ersten-mal-covid-19-erkrankung-antikoerpern-behandelt)



We support life